Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income (loss) including noncontrolling interests in operating subsidiaries	$ (157,478)	$ (66,662)	$ (58,842)
Adjustments to reconcile net income (loss) including noncontrolling interests in operating subsidiaries to net cash provided by (used in) operating activities:
Depreciation and amortization	53,289	54,049	49,275
Non-cash stock compensation	11,048	18,115	27,894
Excess tax benefits from stock-based compensation	0	0	1,398
Provision for deferred income taxes	0	(1,736)	(26,746)
Impairment of Patent-Related Intangible Assets	74,731	3,497	4,619
Impairment of Goodwill	30,149	0	0
Other	(109)	(28)	12
Changes in assets and liabilities:
Increase (Decrease) in Restricted Cash	(10,725)	0	0
Accounts receivable	(13,332)	(13,827)	3,502
Prepaid expenses and other assets	(619)	3,154	(5,300)
Accounts payable and accrued expenses / costs	2,570	3,718	2,740
Royalties and contingent legal fees payable	527	3,904	(2,061)
Net cash provided by (used in) operating activities	(9,949)	4,184	(3,509)
Cash flows from investing activities:
Purchase of property and equipment	(8)	(109)	(675)
Purchase of available-for-sale investments	(23,296)	(109,963)	(279,693)
Sale of available-for-sale investments	82,115	182,115	239,370
Patent acquisition costs	(19,504)	(42,746)	(25,061)
Net cash provided by (used in) investing activities	39,307	29,297	(66,059)
Cash flows from financing activities:
Payments of Dividends	(25,434)	(25,039)	(18,633)
Distributions to noncontrolling interests in operating subsidiary	(4,105)	(867)	0
Proceeds from the exercise of stock options	938	206	486
Repurchases of common stock	0	0	(7,926)
Contributions from noncontrolling interests in operating subsidiary, net of issuance costs	0	0	1,920
Excess tax benefits from stock-based compensation	0	0	(1,398)
Net cash provided by (used in) financing activities	(28,601)	(25,700)	(25,551)
Increase in cash and cash equivalents	757	7,781	(95,119)
Cash and cash equivalents, beginning	134,466	126,685	221,804
Cash and cash equivalents, ending	135,223	134,466	126,685
Patent acquisition costs included in accrued expenses	$ 1,000	$ 16,700	$ 4,000